Insider Sell: EVP, Chief Technical Ops. Off. ...
On February 21, 2024, Atkinson Edward Morrow III, EVP, Chief Technical Ops. Off. of Vertex Pharmaceuticals Inc (VRTX), sold 1,201 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Vertex Pharmaceuticals Inc is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has a portfolio of products and a pipeline of investigational drugs designed to treat cystic fibrosis and other serious diseases.
Over the past year, the insider has sold a total of 2,114 shares of Vertex Pharmaceuticals Inc and has not made any purchase of the stock.
The insider transaction history for Vertex Pharmaceuticals Inc shows a pattern of selling activity, with 61 insider sells and no insider buys over the past year.
On the day of the insider's recent sell, shares of Vertex Pharmaceuticals Inc were trading at $421.77, resulting in a market cap of $111.10 billion.
The stock's price-earnings ratio stands at 30.97, which is above both the industry median of 28.64 and the company's historical median price-earnings ratio.
According to the GuruFocus Value, with a stock price of $421.77 and a GF Value of $349.36, Vertex Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.21, indicating that the stock is modestly overvalued.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
